1. WHO . Solar ultraviolet radiation: Global burden of disease from solar ultraviolet radiation. 2006. [Online]. http://www.who.int/uv/publications/solaradgbd/en
Google Scholar2. Sekulic, A., Mangold, AR., Northfelt, DW., LoRusso, PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013;25(3):218-223.doi:10.1097/CCO.0b013e32835ff438 23493193
Google Scholar | Crossref | Medline3. Haves, AW., Schaffer, PR., Carucci, JA. The impact of inoperable advanced basal cell carcinoma: the economic, physical, and psychological burden of the disease. J Drugs Dermatol. 2013;12(10 Suppl):S151-153.24085061
Google Scholar | Medline4. Epstein, EH . Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743-754.doi:10.1038/nrc2503 18813320
Google Scholar | Crossref | Medline5. Sekulic, A., Migden, MR., Oro, AE et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.doi:10.1056/NEJMoa1113713 22670903
Google Scholar | Crossref | Medline | ISI6. Basset-Séguin, N., Hauschild, A., Kunstfeld, R et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334-348.doi:10.1016/j.ejca.2017.08.022 29073584
Google Scholar | Crossref | Medline7. Apalla, Z., Papageorgiou, C., Lallas, A et al. Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy. Clin Cosmet Investig Dermatol. 2017;10:171-177.doi:10.2147/CCID.S101330 28546761
Google Scholar | Crossref | Medline8. Basset-Seguin, N., Hauschild, A., Grob, J-J et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729-736.doi:10.1016/S1470-2045(15)70198-1 25981813
Google Scholar | Crossref | Medline | ISI9. Bernia, E., Llombart, B., Serra-Guillén, C et al. Experience with vismodegib in the treatment of advanced basal cell carcinoma at a cancer center. Actas Dermosifiliogr. 2018;109(9):813-820.doi:10.1016/j.ad.2018.06.003 30055751
Google Scholar | Crossref | Medline10. Chang, ALS., Arron, ST., Migden, MR et al. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016;11(1):120. doi:10.1186/s13023-016-0506-z 27581207
Google Scholar | Crossref | Medline11. Eisenhauer, EA., Therasse, P., Bogaerts, J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version1.1). Eur J Cancer. 2009;45(2):228-247.doi:10.1016/j.ejca.2008.10.026 19097774
Google Scholar | Crossref | Medline | ISI12. Dréno, B., Kunstfeld, R., Hauschild, A et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404-412.doi:10.1016/S1470-2045(17)30072-4 28188086
Google Scholar | Crossref | Medline13. Kwon, GP., Ally, MS., Bailey-Healy, I et al. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC). J Am Acad Dermatol. 2016;75(1):213-215.doi:10.1016/j.jaad.2016.02.1235 27317518
Google Scholar | Crossref | Medline14. Lacouture, ME., Dréno, B., Ascierto, PA et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218-1229.doi:10.1634/theoncologist.2016-0186 27511905
Google Scholar | Crossref | Medline15. Herms, F., Lambert, J., Grob, J-J et al. Follow-Up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter French study of 116 patients. J Clin Oncol. 2019;37(34):3275-3282.doi:10.1200/JCO.18.00794 31609670
Google Scholar | Crossref | Medline16. Xie, P., Lefrançois, P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(6):1089-1100.doi:10.1016/j.jaad.2018.07.004 30003981
Google Scholar | Crossref | Medline